Matrix metalloproteinase-2 mediates a mechanism of metabolic cardioprotection consisting of negative regulation of the sterol regulatory element-binding protein-2/3-Hydroxy-3-Methylglutaryl-CoA reductase pathway in the heart

Hypertension

Volumn 65, Issue 4, 2015, Pages 882-888

  Wang, Xiang ^a   Berry, Evan ^a   Hernandez Anzaldo, Samuel ^a   Takawale, Abhijit ^b   Kassiri, Zamaneh ^b   Fernandez Patron, Carlos ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

cardiomegaly; hydroxymethylglutaryl CoA reductase inhibitors; matrix metalloproteinase 2; sterol regulatory element binding proteins

Indexed keywords

ANGIOTENSIN II; CHEMOKINE; GELATINASE A; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; LIVER X RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A; ACYL COENZYME A; RNA; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FIBROSIS; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HYPERTENSION; IMMUNOREACTIVITY; INFLAMMATION; MALE; MARKER GENE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE; ANIMAL; BIOSYNTHESIS; BLOOD PRESSURE; C57BL MOUSE; CARDIOMEGALY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HEART MUSCLE CELL; IMMUNOBLOTTING; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ACYL COENZYME A; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; REAL-TIME POLYMERASE CHAIN REACTION; RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRANSCRIPTION FACTORS;

EID: 84929129164     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04989     Document Type: Article

References (23)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365: 217-223. doi: 10.1016/S0140-6736(05)17741-1
2. Wang X, Bosonea AM, Odenbach J, Fernandez-Patron C. Molecular signals elicited by GPCR agonists in hypertension, cardiovascular remodeling: are MMPs and ADAMs elusive therapeutic targets?. Curr Hypertens Rev. 2012; 8: 159-180
3. Wang X, Bosonea AM, Fernandez-Patron C. Metalloproteinases: key and common mediators of multiple GPCRs and candidate therapeutic targets in models of hypertensive cardiac disease. Drug Discov Today Dis Models. 2012; 9: e103-e108. doi: 10.1016/j.ddmod.2012.04.003
4. Fernandez-Patron C, Filep JG. GPCRs in cardiovascular pathologies. Drug Discov Today Dis Mech. 2012; 9: e75-e78
5. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol. 2004; 16: 558-564. doi: 10.1016/j. ceb.2004.07.010
6. Lijnen HR, Collen D. Matrix metalloproteinase system deficiencies and matrix degradation. Thromb Haemost. 1999; 82: 837-845
7. Matsusaka H, Ikeuchi M, Matsushima S, Ide T, Kubota T, Feldman AM, Takeshita A, Sunagawa K, Tsutsui H. Selective disruption of MMP-2 gene exacerbates myocardial inflammation and dysfunction in mice with cytokine-induced cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005; 289: H1858-H1864. doi: 10.1152/ajpheart.00216.2005
8. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest. 2005; 115: 599-609. doi: 10.1172/JCI22304
9. Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T, Sunagawa K, Kinugawa S, Tsutsui H. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension. 2006; 47: 711-717. doi: 10.1161/01. HYP.0000208840.30778.00
10. Liao JK. Statin therapy for cardiac hypertrophy and heart failure. J Investig Med. 2004; 52: 248-253
11. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997; 89: 331-340
12. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Posttranslational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov. 2007; 6: 541-555. doi: 10.1038/nrd2221
13. Berry E, Bosonea AM, Wang X, Fernandez-Patron C. Insights into the activity, differential expression, mutual regulation, and functions of matrix metalloproteinases and a disintegrin and metalloproteinases in hypertension and cardiac disease. J Vasc Res. 2013; 50: 52-68. doi: 10.1159/000345240
14. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, Liao JK. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001; 108: 1429-1437. doi: 10.1172/JCI13350
15. Zile MR, Desantis SM, Baicu CF, Stroud RE, Thompson SB, McClure CD, Mehurg SM, Spinale FG. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail. 2011; 4: 246-256. doi: 10.1161/CIRCHEARTFAILURE.110.958199
16. Schmid-Schönbein GW. An emerging role of degrading proteinases in hypertension and the metabolic syndrome: autodigestion and receptor cleavage. Curr Hypertens Rep. 2012; 14: 88-96. doi: 10.1007/s11906-011-0240-9
17. Odenbach J, Wang X, Cooper S, Chow FL, Oka T, Lopaschuk G, Kassiri Z, Fernandez-Patron C. MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension. 2011; 57: 123-130. doi: 10.1161/HYPERTENSIONAHA.110.159525
18. Shmeeda H, Petkova D, Barenholz Y. Cholesterol homeostasis in cultures of rat heart myocytes: relationship to cellular hypertrophy. Am J Physiol. 1994; 267(5 Pt 2): H1689-H1697
19. Shmeeda H, Petkova D, Barenholz Y. Cholesterol distribution in rat heart myocytes. Am J Physiol. 1995; 268(2 Pt 2): H759-H766
20. Yokoyama M, Seo T, Park T, Yagyu H, Hu Y, Son NH, Augustus AS, Vikramadithyan RK, Ramakrishnan R, Pulawa LK, Eckel RH, Goldberg IJ. Effects of lipoprotein lipase and statins on cholesterol uptake into heart and skeletal muscle. J Lipid Res. 2007; 48: 646-655. doi: 10.1194/jlr. M600301-JLR200
21. Jung HO, Uhm JS, Seo SM, Kim JH, Youn HJ, Baek SH, Chung WS, Seung KB. Angiotensin II-induced smooth muscle cell migration is mediated by LDL receptor-related protein 1 via regulation of matrix metalloproteinase 2 expression. Biochem Biophys Res Commun. 2010; 402: 577-582. doi: 10.1016/j.bbrc.2010.10.019
22. Lacchini R, Jacob-Ferreira AL, Luizon MR, Gasparini S, Ferreira-Sae MC, Schreiber R, Nadruz W Jr, Tanus-Santos JE. Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J Hum Hypertens. 2012; 26: 171-177. doi: 10.1038/jhh.2011.8
23. Tuysuz B, Mosig R, Altun G, Sancak S, Glucksman MJ, Martignetti JA. A novel matrix metalloproteinase 2 (MMP2) terminal hemopexin domain mutation in a family with multicentric osteolysis with nodulosis and arthritis with cardiac defects. Eur J Hum Genet. 2009; 17: 565-572. doi: 10.1038/ejhg.2008.204